Illuminating Alternative Strategies to Treat Targeted Chemotherapy-Resistant Sporadic Basal Cell Carcinoma.

Abstract excerpt

Sporadic and basal cell nevus syndrome basal cell carcinomas show differential response rates to Smoothened inhibitors. Chiang et al. demonstrate notable decreases in UV-induced mutagenesis, total mutation load, genomic instability, and drug-resistant mutations among basal cell nevus syndrome basal cell carcinomas using whole exome sequencing, which may explain the differences in drug response rates.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Basal Cell Nevus Syndrome
• Share to Carcinoma, Basal Cell
• Share to Genomic Instability